ArticleMedical & biological engineering & computing2026
Mel-DEPTHS: a benchmark dataset for epidermis and tumor segmentation for melanoma staging.
Article in Medical & biological engineering & computing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Accurate delineation of epidermis and tumor boundaries is central to melanoma staging, yet pixel-level annotation on whole-slide images (WSIs) is labor-intensive and inconsistent across observers. Advancing this field requires standardized, publicly available benchmarks with expert-validated labels. We introduce Mel-DEPTHS, a new benchmark dataset for epidermis and tumor segmentation, designed to accelerate and standardize research for automated melanoma staging. Mel-DEPTHS comprises 50 anonymized melanoma WSIs (40x, 0.25[Formula: see text]m/pixel) with pixel-level masks for epidermis and tumor regions. Clinical variables such as invasion depth, ulceration, and pT stage are provided alongside fixed train/test partitions to ensure reproducibility. To mitigate annotation burden, we developed an Expert-Supervised Iterative Self-Training (ESIST) protocol: a pretrained model generates pseudo-labels, which dermatopathologists iteratively refine for retraining. We benchmarked six state-of-the-art segmentation models (UNet, UNet++, UNet3+, UPerNet, TransUNet, ConvUNeXt) using WSI-level precision, recall, IoU, and Dice. TransUNet achieved the best performance, closely followed by ConvUNeXt and UperNet. Three-fold cross-validation also confirmed consistent model rankings and label robustness. Mel-DEPTHS provides the fidelity and diversity necessary for clinically meaningful segmentation. It establishes a standardized benchmark and fosters reproducibility in computational pathology.
Indexed as
Identifiers
42593600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.